How to use Lisocabtagene maraleucel

Lisocabtagene maraleucel (Lisocabtagene maraleucel) is prepared from the patient's own white blood cells. These are extracted from the blood, genetically modified in the laboratory, and then infused back into the patient. The drug is given as a single intravenous infusion and can only be given to patients whose own cells have been used to make the drug.

Prior to treatment with lisocabbutanol, patients should undergo a short course of systemic therapy to clear their existing white blood cells, and they should be given other medications just before infusion to reduce the risk of infusion reactions. A drug called tocilizumab (or a suitable alternative if unavailable due to shortages) and emergency equipment must be provided in case patients develop a potentially serious side effect called cytokine release syndrome.

Patients with relapsed or refractory B-cell lymphoma (LBCL) after first-line therapy A single dose of lisocabeta root contains 90-110 Patients with relapsed or refractory large B-cell lymphoma after two or more courses of therapy Single-dose lisocabeta root contains 50-110 × 106 CAR-positive live T cells (consisting of a 1:1 CAR-positive live T cell mix of CD8 and CD4 components), each component is packaged in 1 to 4 single-dose vials.

Since Lisocaptagen has been on the market for a short time, there may be less information on its price and other related information.